Last reviewed · How we verify
HMS5552
HMS5552 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells.
HMS5552 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | HMS5552 |
|---|---|
| Also known as | Glucokinase Activator (GKA), Sinogliatin, GKA |
| Sponsor | Hua Medicine Limited |
| Drug class | Glucokinase activator |
| Target | Glucokinase (GCK) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
HMS5552 activates glucokinase, a key enzyme in glucose metabolism within pancreatic beta cells. By increasing glucokinase activity, the drug improves the glucose-sensing capacity of beta cells, leading to enhanced insulin secretion in response to elevated blood glucose levels. This mechanism helps restore more physiological insulin secretion patterns in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disorders
Key clinical trials
- Drug Interaction Study Between Dorzagliatin and Empagliflozin (PHASE1)
- Drug Interaction Study Between Dorzagliatin and Sitagliptin (PHASE1)
- A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers (PHASE1)
- Long-term Efficacy and Safety of HMS5552 in T2DM Subjects (PHASE3)
- The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus
- Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects (PHASE3)
- A Clinical Study to Access the Pharmacokinetics of HMS5552 in Renal Impaired Subjects and Healthy Volunteers (PHASE1)
- A Multi-center 12-week Study of HMS5552 in T2DM (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HMS5552 CI brief — competitive landscape report
- HMS5552 updates RSS · CI watch RSS
- Hua Medicine Limited portfolio CI